Mini Keynote Symposium on Cancer Research

Host: Institut Català d'Oncologia (ICO) i IGTP

Date and time: | 15:00-19:00

Venue: Auditorium, Institut de Recerca contra la Leucèmia Josep Carreras, Campus Can Ruti

Updates in advances in translational research in precision medicine for cancer treatments

This mini-synmposium featuring experts in research in precision medicine is aimed at basic, translational and clinical researchers working on precision methods to improve cancer treatments


BRAFV600E& BRAF-inactivating mutations in NSCLC: Approaches to suppress the
evolution to resistance
R. Rosell

PAK signaling in NSCLC & other tumors
H. Hernando

PAK inhibitors & combinatory approaches in lung cancer cell lines
M. Ito

  • IPA-3, OTSSP167, bosutinib, thonzonium bromide, AT13148 and reversine

Bottom-line: MELK (maternal embryonic leucine kinase) - a novel molecular target
R. Rosell

PIM1 kinase in triple negative breast cancer & in EGFR mutant NSCLC
J. Bracht

MET alterations (MET exon 14 mutations, MET amplification, MET exon 7-8 mutations
in gastric adenocarcinoma, lung squamous cell carcinoma, lung adenocarcinoma &
I. Attili

  • Tepotinib, savolitinib, cabozantinib, crizotinib,
  • Combinations with PIM and SRC inhibitors

Early NSCLC: The Japan experience
M. Ito

Tumor cell streaming related to MENAINV & HGF/C-Met signaling pathway
Bottom-line: The liaison of MET and PIM - N. Karachaliou

Landscape in KRAS mutant lung cancers and therapeutic principles
C. Codony

shRNA loss of function technology in KRAS mutated cell line
D. Llige

CDK4/6 inhibition in KRAS tumors
M.A. Molina

Antitumor activity of CDK4/6i in mesothelioma
E. Nadal

CDCP1 in KRAS mutant NSCLC
M. de los Llanos Gil

Bottom-line: Snapshot of immunotherapy - CDK4/6 inhibitors & afatinib as enhancers
of immune checkpoint inhibitors - R. Rosell

Coactivation of RTKs in EGFR mutant cells & EGFR mutant NSCLC patients

AXL plasma protein levels
J. Berenguer

Role of tropomyosin related kinase B (TrkB) & brain derived neurotrophic factor
(BDNF) in EGFR mutant NSCLC & breast cancer
I. Chaib

Squamous cell carcinoma of head and neck: multiple new therapies
I. Chaib

Bottom-line: PALB2 at the crossroads of DNA repair: PARP inhibition, WEE1 kinase
inhibitors & AXL in several types of cancer - R. Rosell

From bench to bed: Anti-EGF vaccine in treatment naïve and resistant EGFR mutant
cell lines
J. Codony

EPICAl trial
S. Viteri

Why is afatinib better than other EGFR TKIs?
R. Rosell

Immune checkpoint inhibitors & targeted therapy
I. Attili

An approach for anti-PD-1/PD-L1 monotherapy resistant cancers
M. Gonzalez Cao

Speaker affiliations

  • Rafael Rosell, Director, Cancer Biology & Precision Medicine Program,Catalan Institute of Oncology, Germans Trias i Pujol Hospital (HUGTP) and Institute (IGTP), Badalona
  • Henar Hernando, Senior Scientist, Drug Development,IGTP, Edifici Muntanya, Badalona
  • Masaoki Ito, Coyote Research Group,Pangaea Oncology, Barcelona
  • Ilaria Attili, Coyote Research Group,Pangaea Oncology, Barcelona
  • Jill Bracht, Coyote Research Group,Pangaea Oncology, Barcelona
  • Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Barcelona
  • Niki Karachaliou, Coyote Research Group, Pangaea Oncology, Barcelona
    Director of Medical Oncology Department, Hospital Universitari Sagrat Cor, IOR, Quirón-Dexeus, Barcelona
  • Carles Codony, Coyote Research Group,Pangaea Oncology, Barcelona
  • David Llige, Laboratory Technician,IGTP, Edifici Muntanya, Badalona
  • Miguel Angel Molina-Vila, Laboratory Technical Director, Pangaea Oncology, Barcelona
  • Ernest Nadal, Medical Oncologist, Catalan Institute of Oncology, L'Hospitalet, Barcelona
  • Maria de los Llanos Gil, Medical Oncologist,IOR, Quirón-Dexeus, Barcelona
  • Imane Chaib, Postdoctoral Researcher, IGTP, Edifici Muntanya, Badalona
  • Jordi Codony, Coyote Research Group, Pangaea Oncology, Barcelona
  • Santiago Viteri, Medical Oncologist, IOR, Quirón-Dexeus, Barcelona
  • María González-Cao, Medical Oncologist, IOR, Quirón-Dexeus, Barcelona


For FREE REGISTRATION, email lourdes.franquet.oncology(ELIMINAR)@gmail.comindicating your full name and affiliation


The Mini Symposium is on the Can Ruti Campus in Badalona. 

Institut de Recerca contra la Leucèmia Josep Carreras (IJC)
Ctra. de Can Ruti, Camí de les Escoles s/n
08916 Badalona, Barcelona, Spain
Tel: (+34) 93 554 3050

GPS: 41°29'06.66"N 2°14'21.27"E
From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is
well signed from the exit 21 (Badalona Centre) of the B20.